Pharmacoenhancement of Protease Inhibitors
Authors:
- Walid KhayrWKWalid Khayr
- 1 January 2006
- journal article
- review article
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 13 (1) , 57-63
Abstract
Toxicity, adherence problems, and virological failure may limit treatment by protease inhibitor-containing regimens at standard doses. Addition of low-dose ritonavir results in a high plasma concentration of coadministered protease inhibitor resulting in decreased pill burden, a reduction in the number of doses, fewer food and/or fluid restrictions, and a higher rate of virological suppression. These effects are due to improved pharmacokinetics of coadministered protease inhibitors.Keywords
This publication has 29 references indexed in Scilit:
- Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 TrialThe Journal of Infectious Diseases, 2003
- A Review of Low-Dose Ritonavir in Protease Inhibitor Combination TherapyClinical Infectious Diseases, 2003
- Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV InfectionNew England Journal of Medicine, 2002
- Simplifying Protease Inhibitor Therapy with Once-Daily Dosing of Saquinavir Soft-Gelatin Capsules/Ritonavir (1600/100 mg): HIVNAT 001.3 StudyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Steady-State Pharmacokinetics of Twice-Daily Dosing of Saquinavir Plus Ritonavir in HIV-1–Infected IndividualsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Drug Resistance and Predicted Virologic Responses to Human Immunodeficiency Virus Type 1 Protease Inhibitor TherapyThe Journal of Infectious Diseases, 2000
- Outcome and Predictors of Failure of Highly Active Antiretroviral Therapy: One‐Year Follow‐Up of a Cohort of Human Immunodeficiency Virus Type 1–Infected PersonsThe Journal of Infectious Diseases, 1999
- Ritonavir and saquinavir combination therapy for the treatment of HIV infectionAIDS, 1999
- Relationships Between Exposure to Saquinavir Monotherapy and Antiviral Response in HIV-Positive PatientsClinical Pharmacokinetics, 1999
- The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Journal of Clinical Investigation, 1998